Theme Leader

Theme Leader

Professor Timothy P. Hughes, MD, FRACP, FRCPA, MBBS, FAAHMS

Professor Timothy Hughes is the Precision Medicine Theme Leader at the South Australian Health and Medical Research Institute (SAHMRI); Cancer Council Chair in Cancer Research and Consultant Haematologist at the Royal Adelaide Hospital. He is also Chair of the International Chronic Myeloid Leukemia Foundation (iCMLf) and an inaugural Fellow of the Australian Academy of Health and Medical Sciences (AAHMS).

Professor Hughes had a significant leadership role in the establishment of the molecular response criteria and kinase domain mutation screening guidelines that are used world-wide to monitor response and resistance in chronic myeloid leukaemia (CML). He has been a principal investigator on many of the key Global and Australian CML trials that have shaped the way tyrosine-kinase inhibitors (TKIs) are selected and sequenced. He has been a leader in the area of treatment-free remission (TFR) and influential in the recent recommendations to make TFR a mainstream goal of therapy. He has published over 290 papers with over 45,000 citations.

10 significant publications

H Factor 83 Citations 45542

1.Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Henslee ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM and Radich J. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed patients with chronic myeloid leukemia. 2003 New England Journal of Medicine 349:1423-32 CIT 1369 This landmark paper was the first to define MMR and to demonstrate that achievement of MMR was predictive of a very low risk of disease progression.

2.Michor F, Hughes TP, Iwasa Y, Branford S, Shah N, Sawyers C, Nowak A. Dynamics of chronic myeloid leukaemia. 2005 Nature (A*) 435(7046):1267-70 CIT 777  The first mathematical model of a human cancer predicted that leukaemic stem cells may not be reduced by imatinib. The primary data used for this mathematical model was produced in our lab.

3.Hughes TP, Deininger MW, Hochhaus A, Branford S, Radich JP, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman J. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors – Review and recommendations for ‘harmonizing’ current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. 2006 Blood (A*) 108(1) 28-37 CIT 1188. I led the global move to standardise PCR measurement of MRD in CML.

4.Druker B, Guilhot F, O’Brien S, Gathman I, Kantasrjian H, Gattermann N, Deininger M, Silver R, Goldman J, Stone R, Cervantes F, Hochhaus A, Powell B, Gabrilove J, Rousselot P, Reiffers J, Cornelissen J, Hughes TP, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen J, Radich J, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson R. Five-year follow up of patients receiving Imatinib for chronic myeloid leukaemia. 2006 New England Journal of Medicine (A*) 355 (2408-17) CIT 3448

5.Hughes TP, Branford S White DL, Reynolds J, Koelmeyer, Seymour JF, Taylor K, Arthur C, Schwarer A, Morton J, Cooney J, Leahy MF, Rowling P, Catalano J, Hertzberg M, Filshie R, Mills AK, Fay K, Durrant S, Januszewicz, Joske D, Underhill C, Dunkley S, Lynch K, Grigg A on behalf of the Australasian Leukaemia and Lymphoma Group. Impact of early dose intensity on cytogenetic and molecular responses in chronic phase CML patients receiving 600 mg/day. 2008 Blood (A*) 112(10) 3965-3973 CIT 163

6.Hughes TP, Saglio G, Branford S, Soverini S, Kim D-W, Muller MC, Martinelli G, Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, Radich J, Hochhaus A. Impact of baseline BCR-ABL mutations on response to Nilotinib in patients with chronic myeloid leukaemia in chronic phase. 2009 Journal of Clinical Oncology (A*) 27(25) 4204-10 CIT 314 JCO is the premium oncology journal. I led the international panel that reviewed the mutation data from this trial to identify a limited number of mutations as resistant to nilotinib.

7.Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Goldman JM, Shah NP, Kantarjian H; PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. New England Journal Medicine. 2013 369(19)1783-1796 CIT 655

8. Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, Marzinzik A, Pelle X, Donovan J, Zhu W, Buonamici S, Hassan Q, Lombardo F, Iyer V, Palmer M, Berellini G, Dodd S, Thohan S, Bitter H, Branford S, Ross D, Hughes TP, Petruzzelli L, Vanasse KG, Warmuth M, Hofmann F, Keen N, Sellers WR. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL. Nature. 30 March 2017 543 (7647) 733-737 CIT 66

9. Hochhaus A, Larson RA, Guilhot F, Radich J, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann C, Menssen H, Kantarjian H, O’Brien S, Druker B. IRIS Final Analysis: Long-Term outcomes with Imatinib treatment for CML. New England Journal Medicine. March 2017 376 (10) 917-927 CIT 190

10.Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, Ailawadhi S, Lipton JH, Turkina AG, Paz R, Moiraghi B, Nicolini FE, Dengler J, Sacha T, Takahashi N, Fellague-Chebra R, Acharya S, Wong S, Jin Y, Hughes TP. Treatment-Free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, Phase 2, open-label study. Annals of Internal Medicine Feb 2018  CIT 18

Get in touch
+61 8 8128 4000 info@sahmri.com
You can't miss us!
North Terrace Adelaide 5000 South Australia
Postal Address
PO BOX 11060 Adelaide 5001 South Australia
Key Partners
SAHMRI is located on the traditional lands of the Kaurna Nation.

The SAHMRI community acknowledges and respects the traditional owners, the family clans who are the Kaurna Nation from the Adelaide Plains region of South Australia. We acknowledge the clans of the Kaurna Nation and the sacred knowledge they hold for their country. We pay our respects to the Kaurna Nation, their ancestors and the descendants of these living family clans today.